Epibiotech Statistics

Total Valuation

Epibiotech has a market cap or net worth of KRW 25.12 billion.

Market Cap	25.12B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Epibiotech has 2.31 million shares outstanding.

Current Share Class	2.31M
Shares Outstanding	2.31M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	36.94%
Owned by Institutions (%)	2.45%
Float	412,652

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	55.87
PB Ratio	3.98
P/TBV Ratio	4.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.42.

Current Ratio	1.37
Quick Ratio	1.29
Debt / Equity	0.42
Debt / EBITDA	n/a
Debt / FCF	-0.51
Interest Coverage	-55.08

Financial Efficiency

Return on equity (ROE) is -62.73% and return on invested capital (ROIC) is -29.34%.

Return on Equity (ROE)	-62.73%
Return on Assets (ROA)	-28.39%
Return on Invested Capital (ROIC)	-29.34%
Return on Capital Employed (ROCE)	-76.75%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.04
Inventory Turnover	14.21

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.79% in the last 52 weeks. The beta is 1.12, so Epibiotech's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	+15.79%
50-Day Moving Average	10,724.20
200-Day Moving Average	11,866.85
Relative Strength Index (RSI)	46.94
Average Volume (20 Days)	97

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Epibiotech had revenue of KRW 449.62 million and -5.06 billion in losses. Loss per share was -2,966.00.

Revenue	449.62M
Gross Profit	272.25M
Operating Income	-5.04B
Pretax Income	-5.06B
Net Income	-5.06B
EBITDA	-4.29B
EBIT	-5.04B
Loss Per Share	-2,966.00

Full Income Statement

Balance Sheet

The company has 3.49 billion in cash and 2.64 billion in debt, giving a net cash position of 851.49 million or 369.11 per share.

Cash & Cash Equivalents	3.49B
Total Debt	2.64B
Net Cash	851.49M
Net Cash Per Share	369.11
Equity (Book Value)	6.31B
Book Value Per Share	3,313.83
Working Capital	1.00B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.42 billion and capital expenditures -699.36 million, giving a free cash flow of -5.12 billion.

Operating Cash Flow	-4.42B
Capital Expenditures	-699.36M
Free Cash Flow	-5.12B
FCF Per Share	-2,221.29

Full Cash Flow Statement

Margins

Gross Margin	60.55%
Operating Margin	-1,120.59%
Pretax Margin	-1,124.91%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Epibiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-20.13%
FCF Yield	-20.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Epibiotech has an Altman Z-Score of -3.39 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.39
Piotroski F-Score	1